BCR and chronic myelogenous leukemia, BCR-ABL1 positive: One example here is Gleevec, which is a drug that acts as a selective inhibitor of the chronic myeloid leukemia (CML) causal fusion transcript BCR-ABL tyrosine kinase [23].